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The pathogenesis of parathyroid gland hyperplasia
in chronic renal failure
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A 58-year-old female dialysis patient was admitted to the Nephrology
Department at the Hopital Necker because of severe secondary hyper-
parathyroidism. She had had chronic interstitial nephritis with slowly
progressive chronic renal failure for more than 10 years. Intermittent
home hemodialysis treatment was started 18 years ago. Symptoms and
signs of hyperparathyroidism were present before the patient developed
end-stage renal failure, and the severity of osteitis fibrosa progressed
despite the initiation of renal replacement therapy.
Thirteen years ago, the patient first underwent a surgical neck explora-
tion. One large parathyroid gland weighing 4500 mg was removed. One
other gland was identified, which was biopsied and had a normal aspect; it
was left in place. The remaining glands could not be identified. Operative
and light microscopic findings were compatible with the diagnosis of
primary adenoma. The plasma calcium concentration decreased markedly
immediately after parathyroidectomy, and radiologic signs of osteitis
fibrosa regressed.
Severe aluminum intoxication, mainly due to aluminum-contaminated
dialysis fluid, was diagnosed 9 years ago. An appropriate dialysis water
purification system with reverse osmosis was put in place, and the patient
received deferoxamine treatment for several months 8 years ago. Soon
thereafter, recurrence of hyperparathyroidism became evident. Several
attempts at treating the osteitis fibrosa medically were undertaken, first
using calcium carbonate and thereafter small doses of oral 1-alpha
cholecalciferol. Several transient hypercalcemic and hyperphosphatemic
episodes finally led to cessation of the administration of vitamin D
derivatives.
Three years ago, the plasma calcium level ranged between 2.5 and 2.7
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mmol/liter, and the plasma phosphorus between 1.6 and 2.2 mmol/liter.
The serum total alkaline phosphatases were elevated as much as 6 times
the upper limit of normal, and plasma intact PTH was 1200 pg/mI (normal
range, 10—65 pg/ml). Cervical ultrasound exploration indicated the pres-
ence of a left infrathyroid lesion suggestive of an enlarged parathyroid
gland. Cervico-mediastinal CT scan was suggestive of both a retrothyroid
and an infrathyroid parathyroid gland. A second parathyroidectomy was
performed, which led to the removal of two parathyroid glands, weighing
200 and 50 mg, respectively. At operative and light microscopic examina-
tion, the first gland had an aspect of diffuse hyperplasia, whereas the
second had a normal aspect. Several parathyroid tissue fragments were
immediately autografted into the left forearm flexor muscle.
During the days after the operation, the patient's plasma calcium and
phosphorus levels did not decrease. Plasma intact PTH remained elevated
during more prolonged followup. Five months after the second parathy-
roidectomy, the PTH level was 1350 pg/mI. Osteoarticular pain failed to
resolve, and pruritus persisted.
During the subsequent 2 years, the patient underwent a number of
investigations to detect the site of persistent, excessive PTH secretion, and
in particular to identify a possible supernumerary parathyroid gland. The
possibility of recurrent hyperparathyroidism at the site of parathyroid
autotransplantation in the left arm was eliminated because of a negative
"tourniquet" test, the absence of an echogenic image at ultrasound
examination, and a negative imaging by thallium-technetium subtraction
scintigraphy at the site. However, the latter examination also was per-
formed in the neck region and revealed an ectopic uptake of the tracer in
the left supraclavicular area. In contrast, extensive venous blood sampling
led to the finding of an excessively increased PTH level in the right
subclavian vein. Magnetic resonance imaging (done in TI, T2, and STiR
mode) was not contributory. Repeat echography and subsequent arteriog-
raphy both confirmed the presence of a lesion compatible with a super-
numerary parathyroid gland in the left supraclavicular region. An echo-
guided fine-needle cytoaspiration of this lesion revealed an extremely high
PTH concentration in the aspiration fluid.
A third parathyroidectomy performed one year ago confirmed the
preoperative localization and led to the removal of a parathyroid gland
weighing 1800 mg. Light microscopic examination showed that the gland
tissue had a nodular aspect. The operation was followed by a rapid and
marked fall of plasma calcium to 1.59 mmol/liter. Plasma intact PTH
decreased to 36 pg/mI and has remained in the normal range during a one-
year followup.
Discussion
DR. TILMAN B. DRUEKE (Director, Unite 90 de l'INSERM;
Associate Professor, Division of Nephrology, Hôpital Necker, Paris,
France): This woman had long-standing, slowly progressive renal
failure and hyperparathyroidism associated with chronic intersti-
tial nephritis. Her hyperparathyroid state became extremely se-
vere 5 years after she began hemodialysis treatment and required
surgical correction. The discovery and removal of only one grossly
hyperplastic parathyroid gland during neck exploration by an
experienced surgeon came as a surprise; only one other gland
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could be identified, and it was normal. The surgical diagnosis at
that time was primary parathyroid adenoma. During the year after
surgery, clinical and radiologic evidence of osteitis fibrosa re-
solved. Ten years later the patient had recurrent, severe hyper-
parathyroidism, which proved resistant to medical treatment. At
neck exploration, only one moderately hyperplastic parathyroid
gland was found and removed, together with another parathyroid
gland of normal histology, and another piece of tissue, which
proved to be a lymph node. Hyperplastic parathyroid tissue was
immediately autotranspianted into the forearm. Subsequently,
however, because of persistently elevated intact PTH levels in the
circulation, several different localization methods were used in an
attempt to identify the remaining parathyroid tissue. Eventually,
an enlarged, ectopic fourth parathyroid gland was removed, and
the hyperparathyroid state regressed fully. The histologic diagno-
sis was diffuse hyperplasia with nodular transformation, indicating
an abnormal pattern of parathyroid tissue growth.
The experience of this hyperparathyroid dialysis patient high-
lights several points of interest. These include the frequency of
ectopic parathyroid lesions; the question of the most appropriate,
currently available localization techniques to be used in patients
with recurrent hyperparathyroidism; the indications for subtotal
versus total parathyroidectomy, and of immediate autografting;
the problem of a diagnosis of primary parathyroid adenoma
followed by secondary hyperparathyroidism; the significance of
asymmetric hyperplasia of the four parathyroids; the interpreta-
tion of nodular growth within diffusely hyperplastic parathyroid
tissue; and the issue of autonomous, benign, or malignant neo-
plastic growth of parathyroid tissue in situ or after autotranspian-
tation.
The indications for parathyroidectomy and the type of parathy-
roid surgery in patients with chronic renal failure have been
discussed in recent review articles [1, 21. They therefore need not
be addressed here. The issue of using pre-operative localization
methods in uremic patients before a first or a repeated surgical
neck exploration apparently has never been thoroughly addressed.
In particular, the relative value of ultrasound, CT scan, magnetic
resonance, angiography, and various scintigraphic imaging tech-
niques, especially in the exploration of persistent or recurrent
hyperparathyroidism, deserves a review of its own, but this topic is
beyond the scope of the present discussion. I shall focus here on
parathyroid growth during chronic renal failure, not only for the
sake of space but also because new ideas have emerged recently
and better insights have been gained in this area.
Secondary hyperparathyroidism is a common complication of
chronic renal failure. Osteoarticular symptoms and signs comprise
its major clinical expression; osteitis fibrosa or mixed lesions
together with osteomalacia constitute the main forms of histologic
expression in bone. The mechanisms involved in hyperparathroid-
ism can be schematically subdivided into those leading to exces-
sive PTH synthesis and secretion, and those leading to parathy-
roid gland hyperplasia, even though the two are probably closely
interrelated.
Excessive PTH synthesis and secretion
Three main factors are involved in the excess stimulation of
PTH synthesis and secretion in patients with chronic renal failure:
a relative or absolute decrease in plasma calcitriol, a decrease in
plasma ionized calcium, and an increase in plasma phosphorus [3,
4]. The mechanisms by which these factors control PTH release
are complex, and our understanding of their mode of action has
steadily evolved during the last decade. Let me briefly summarize
the most important aspects and major recent contributions in this
area.
Calcitriol. An absolute or relative deficiency of calcitriol pro-
duction in the kidney plays a key role in the initial phase of
chronic renal failure. Calcitriol exerts a negative feedback control
on the parathyroid gland through direct and indirect mechanisms.
It stimulates the intestinal absorption and the skeletal mobiliza-
tion of calcium, thereby increasing plasma Ca2 and inhibiting
PTH secretion indirectly. However, it also elevates plasma phos-
phate, and this elevation counteracts the increase in plasma Ca2
and the inhibition of PTH synthesis by calcitriol.
A direct suppressive action of calcitriol on the PTH gene has
been well established, and the molecular mechanisms of this
action have been characterized. Calcitriol induces a diminished
transcription of mRNA from pre-pro-PTH and translation into
PTH [5—7]. Consequently, an increase in circulating calcitriol
suppresses PTH synthesis, while a decrease stimulates PTH
synthesis. The action of calcitriol proceeds through binding with
specific vitamin D receptors (VDR) in target cells. A decrease in
the number of calcitriol receptors in the parathyroid tissue of
uremic patients has been reported by two groups [8, 9], but this
decrease subsequently has been questioned because of method-
ologic problems in the two studies [10]. A recent study by Fukuda
et a! has shed new light on this controversial issue. These authors
demonstrated a marked decrease in VDR expression in areas of
nodular transformation within hyperplastic parathyroid tissue but
detected no such receptor downregulation in pure hyperplastic
parathyroid tissue [11].
Calcitriol is thought by some to alter the release of synthesized
PTH in response to extracellular Ca2 by improving parathyroid
gland sensitivity to the cation [12]. This mechanism remains
controversial, however [13, 14]. If present, the modulation by
calcitriol of parathyroid gland responsiveness to Ca2 probably
depends on many factors, including the severity of chronic renal
failure, the degree of hyperparathyroidism, steady-state levels of
plasma calcium and phosphorus, the degree of any concomitant
aluminum overload, and possibly local factors within the parathy-
roid cells.
Calcium. Plasma Ca2 is the second major regulating factor of
PTH synthesis and secretion. The direct and rapid stimulatoiy
effect of low plasma Ca2 on PTH secretion and the rapid
suppressive effect of high plasma Ca2 have been understood for
many years. In the short term, a decrease in extracellular Ca2
stimulates PTH secretion within 3 minutes by the parathyroid
gland via the release of stored hormone from preformed secretory
granules. Sustained stimulation by hypocalcemia is associated with
changes in intracellular degradation of PTH, reutilization of
degraded hormone, and mobilization of a secondary storage poo1
[15]. The fraction of intact PTH in the circulation varies inversely
with plasma Ca2 [16]. Thus the ratio of hormone fragments to
intact hormone has been found to be four- to sevenfold higher in
the presence of hypercalcemia compared with hypocalcemia [17].
During time periods from several hours in vitro to days or even
weeks in vivo, a high extracellular Ca2 concentration reduces the
expression of pre-pro-PTH mRNA, and a low concentration
stimulates PTH mRNA expression [18—21]. This more chronic
effect of Ca2 probably is exerted via the recently described
negative calcium-responsive element located at —3.5 kb in the
Nephrology Forum: Parathyroid gland hypetplasia in CRF 261
upstream flanking region of the human PTH gene that confers
responsiveness of the gene to extracellular calcium [221.
A novel transduction mechanism through which Ca2 exerts its
action on the parathyroid cell recently has been described. The
cation binds to a calcium-specific protein located in the cell
membrane (also called "calcium-sensing receptor"). Two calcium
receptors of different molecular size have been cloned by two
independent groups [23, 24]. The calcium receptor is linked to
several cytoplasmic messenger systems by one or more guanine
nucleotide regulatory (G) proteins [25]. It will be interesting to
explore possible changes of the calcium receptor and its signal
transduction in patients with chronic renal failure. This informa-
tion might lead to a better understanding of the abnormal
regulation of PTH secretion at the cellular and molecular level.
Specific agonists for the calcium receptor already have been
synthesized, and the study of their inhibitory effects on PTH
secretion is in progress [26]. This development could constitute a
promising new tool in the prevention and treatment of hyperpara-
thyroidism.
In dynamic terms, the relation between extracellular Ca2 and
PTH is characterized by a sigmoidal relationship [15, 27]. The set
point of Ca2 in vitro, namely, the medium Ca2 concentration
that produces a half-maximal inhibition of PTH secretion, is
higher in parathyroid cells derived from hyperplastic uremic
glands than it is in cells from normal glands [28, 29]. Whether the
sigmoidal relation between plasma Ca2 and PTH is also abnor-
mal in patients with chronic renal failure remains a matter of
controversy. One group of authors has concluded, based on a
number of studies in hemodialysis patients, that the Ca2 set
point and the sensitivity of the parathyroid cell to Ca2 are
increased in the presence of hyperparathyroidism compared with
low-turnover bone disease [15]. In contrast, a recent controlled
study, in which adolescent uremic patients treated by continuous
ambulatory peritoneal dialysis (CAPD) were for the first time
studied in the absence of a concomitant diaysis procedure and
compared with healthy control subjects, showed that neither the
set point nor the slope of the sigmoidal curve was altered [30]. The
latter study needs to be repeated in adult hemodialysis patients
with various degrees and types of secondary hyperparathyroidism,
in the absence of a dialysis session, and to be compared with
healthy volunteers, before we can question the results of most
previous investigations in this field. Differences in patient charac-
teristics and dialysis techniques might be as important as the
methods used to explain such contradictory results.
Phosphorus. Plasma phosphorus generally is normal or even
decreased in early chronic renal failure [31—33]. Hyperphos-
phatemia develops only during more advanced stages. Phosphorus
exerts indirect and possibly also direct stimulating effects on PTH
secretion through several mechanisms. According to the "trade-
off hypothesis" [34], the kidneys' failure to excrete appropriate
amounts of phosphate in advanced chronic renal failure leads to
an elevation of serum phosphate that in turn lowers plasma
ionized calcium physicochemically, via the calcium x phosphate
solubility product. Moreover, it reduces plasma calcitriol via
diminished renal production [35] and leads to a decrease in
intestinal calcium absorption, thereby providing a low calcium
signal to the parathyroid gland. The plasma phosphorus level
depends to a large extent on dietary phosphate as well. A high
phosphate intake, together with increased phosphate retention,
clearly is an extremely important factor in the genesis of second-
ary hyperparathyroidism, because phosphate inhibits all the coun-
terregulatory mechanisms that can moderate the severity of this
complication [36].
Recent studies done in vivo in animals [37, 38] and in patients
[39—41] with advanced chronic renal failure also suggest a direct
stimulatory role of phosphate at the level of the parathyroid gland,
in the absence of changes of serum calcium or calcitriol levels. The
mechanism of such a possible direct effect of phosphate on PTH
secretion, if it exists at all, has not yet been elucidated.
A very recent, preliminary study done in dispersed bovine
parathyroid cells addressed the issue of a direct effect of phos-
phate in vitro. The authors failed to observe any change of PTH
mRNA expression or PTH release in response to changes of the
phosphorus concentration in the incubation medium [421.
Other mechanisms. In addition to the three main factors—
calcitriol, calcium, and phosphorus—numerous other systemic
and local factors also modify parathyroid gland function and PTH
effects at the target organ level, such as reduced peripheral
degradation of PTH, uremic and exogenous toxins including
aluminum [43, 44], metabolic acidosis [45, 46], catecholamines
[47], glucocorticoids [48], estrogens [49], retinoids [50], and
chromogranin A [51], as well as target cell resistance to PTH
associated with PTH receptor downregulation [52] and post-
receptor resistance to PTH action [53].
I should point out that a basal level of PTH release probably
exists as an inherent expression of the total parathyroid cell mass
and would be relatively independent of systemic regulatory fac-
tors. In addition, PTH secretion has a pulsatile pattern that is
subject to circadian variations [54, 55]. One single determination
of plasma PTH, however, appears to be sufficient for the correct
assessment of the parathyroid status, as variations due to pulsatile
secretion are small [56]. In keeping with diurnal changes of PTH
secretion at the whole organ level is the recently described
heterogeneity of PTH release from individual bovine parathyroid
cells [57, 58]. At a high Ca2 concentration in the incubation
medium, a significant fraction of parathyroid cells (80%) did not
secrete PTH; at low Ca2 levels, not only did PTH secretion per
cell increase, but the percentage of cells releasing PTH also
increased. Even at a very low Ca2 concentration, however, nearly
50% of parathyroid cells remained resistant to the Ca2 stimulus.
This finding is in line with the immunohistochemical observation
of polymorphous, patchy staining patterns for PTH of parathyroid
gland tissue, and suggests that individual parathyroid cells or cell
nests appear to cycle among synthetic, secretory, and storage
states [59, 60]. Patchy staining patterns are observed both in
normal parathyroid tissue and in hyperplastic tissue [60].
Parathyroid hype,plasia
The mechanisms involved in the control of normal parathyroid
cell growth, division, and death, and hence in the regulation of
parathyroid gland size, have not yet been elucidated. Mitoses are
very rarely observed in normal parathyroid tissue sampled from
rats [61] and humans (Gogusev J, personal communication); thus,
parathyroid tissue generally has a very slow growth rate under
physiologic conditions. Mitoses also are rare in parathyroid
adenoma [62]. One has to be cautious in interpreting the counting
of mitotic figures, however. Tissue fixation that is too long
delayed, that is applied for too short a time, or that is performed
in fluid of the incorrect pH can reduce the apparent number of
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mitotic figures, probably because the distinction between mitotic
and pyknotic nuclei is blurred [62].
The increase in parathyroid gland size during chronic renal
failure is an important aspect of hyperparathyroidism [61]. The
size of the parathyroid glands increases over time in hemodialysis
patients, as we have shown [63]. Increased gland mass can
contribute on its own to excess PTH secretion, because basal,
calcium-independent PTH secretion parallels increased parathy-
roid gland mass [641.
In chronically uremic rats, the increase in parathyroid gland
mass is mainly, if not solely, due to hyperplasia, with no evidence
of hypertrophy [611. This observation is based on micromorpho-
metric criteria (mean epithelial cell volume per nucleus) and
biochemical determinations (protein/DNA ratio and [3H]-thymi-
dine incorporation). Figure 1 summarizes the potential modes of
involvement of calcium and calcitriol in the pathogenesis of
parathyroid cell growth in chronic renal failure.
Calcitriol. A large body of evidence indicates that the prophy-
lactic use of vitamin D or its derivatives in uremic patients can
prevent parathyroid hyperplasia. The greatest benefit clearly
obtains when calcitriol is administered early in the course of
chronic renal failure. The question then arises as to whether
calcitriol acts mainly or solely via its inhibitory action on the PTH
gene, or whether it might also exert independent effects on
parathyroid cell growth and proliferation. The experimental study
by Szabo and colleagues in uremic rats has shed some light on this
issue [61]. These authors showed that calcitriol administered to
rats in doses only slightly above the physiologic range could
prevent the parathyroid cell proliferation induced by the uremic
state. However, the hormone exerted this action only when given
prophylactically, that is, at the time of subtotal nephrectomy.
]
When calcitriol was started only 21 days after the induction of
uremia, it lost its ability to oppose the stimulation of parathyroid
cell proliferation elicited by chronic renal failure. Even though
this issue has not been specifically examined in this study,
calcitriol must have exerted its usual inhibitory action on PTH
gene expression and PTH plasma level even when administered
only from day 21 onwards after the creation of the uremic state.
Calcitriol might exert its antiproliferative effect on the para-
thyroid gland through an inhibition of the replication-associated
oncogene, c-myc, the expression of which was stimulated by
exposure of bovine parathyroid cells to serum [65]. In contrast, the
expression of the c-fos gene by these cells was unaltered by
calcitriol. A diminished response to calcitriol's inhibitory action
could be due, at least partially, to a decreased number of calcitriol
receptors in the parathyroid tissue of uremic patients, at least in
focal areas within hyperplastic parathyroid tissue [11].
Calcium. Results from a 1991 study using conventional stereo-
logic techniques and dissector methods of serial parathyroid gland
sections differ from what has been reported in the uremic state.
The long-term response of parathyroid tissue to prolonged by-
pocalcemia in rats with normal renal function appeared to be
mainly that of parathyroid cell hypertrophy, not changes in cell
number [66]. The authors of this study had some uncertainty,
however, as to the best way of expressing their experimental
findings. The rats given a calcium-deficient diet had a lower total
body weight at sacrifice than did control animals. When expressed
as parathyroid gland data per rat, parathyroid cell number was not
increased. In contrast, when expressed as cell number per total
body weight, parathyroid cell number was nearly doubled com-
pared with control rats; this observation would indicate hyperpla-
sia. Another study in rats with long-standing hypocalcemia found
no biochemical evidence of parathyroid cell hypertrophy [61].
However, the authors did not observe an increase in cell prolif-
eration either, as evaluated by [3H]-thymidine incorporation, even
though parathyroid gland weight normalized for body weight was
increased nearly threefold. It is probable that the number of
animals was too small (N = 6) for the investigators to determine
significant changes of cell size and/or number secondary to
calcium deficiency.
A small number of studies report a possible effect of incubation
medium Ca2 concentration on parathyroid cell growth. In a rat
parathyroid organ culture system, changing medium Ca2 modi-
fied [3H]-thymidine uptake into DNA [67]. Brandi and associates
subsequently studied cultured bovine parathyroid cells that had
been subjected to multiple doublings in a serum-free medium
containing growth factors and a low Ca2 concentration [681.
They observed an inverse relation between Ca2 concentration
and cell proliferation. In contrast, in a more recent study by
Kremer and colleagues of bovine parathyroid cells maintained in
primary culture for as long as 8 days, alterations in the Ca2
C-
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Fig. 1. Pathogenesis of secondaty hyperparathyroidism in chronic renal
failure. Potential role of calcium depletion, calcitriol deficiency, and other
factors in parathyroid cell hyperplasia and/or hypertrophy.
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concentration of the incubation milieu had no effect on the growth
state of quiescent cells [65]. In addition, varying the medium
calcium level did not influence the time course or the degree of
induction of oncogene c-myc and c-fos expression or the subse-
quent increase in [3H]-thymidine uptake or proliferation of stim-
ulated parathyroid cells. According to the authors of this report
[65], the apparently discrepant results between primary bovine
cell culture experiments and rat whole-organ studies might indi-
cate [3H]-thymidine incorporation into non-parathyroid-cell ele-
ments, as in the whole-gland study by Lee and Roth [671, or
changes of parathyroid cell properties during multiple passages, as
in the study by Brandi and associates [68]. Alternatively, these
results might implicate a requirement for integrity of parathyroid
gland structure in order for effects of calcium on parathyroid cell
proliferation to be expressed, perhaps by release of growth factors
from neighboring cells. To obtain a better insight, we must await
the establishment of a stable human parathyroid cell line in
culture, which would retain the essential functions of this endo-
crine tissue, and which would allow us to separate the action of
calcium from that of calcitriol [27].
Under in-vivo conditions, obviously it is even more difficult to
study the effect of the Ca2 ion per se and in particular to entirely
dissociate the effects of calcium on parathyroid cell growth from
that of vitamin D, especially in the setting of chronic renal failure.
Nodular growth versus diffuse hypeiplasia. In uremic dialysis
patients with long-standing, severe secondary hyperparathyroid-
ism, refractoriness to medical treatment, in particular to calcitriol
administration, has become a frequent clinical problem despite
the considerable progress made in this field during recent years.
The basis for the refractoriness to medical therapy is unclear. It
could be due to a combination of increased functioning gland
mass, abnormalities related to focal vitamin D-receptor defi-
ciency, limited tolerance to calcitriol dosage, altered calcium
sensitivity of individual parathyroid cells, and/or monoclonal
growth of autonomous PTH-secreting cells [11, 69].
In a number of such patients, nodular parathyroid growth
occurs within diffuse hyperplastic tissue [60, 63, 70—72]. The
prevalence and size of nodule formations within the parathyroid
glands of hemodialysis patients increase with time on dialysis 1631.
Anatomically, such nodules are most often multiple; vary in shape,
size, and architectural pattern; and are composed of one or more
cell types [60]. They usually are demarcated by a fibrovascular
stroma or by an abrupt cyto-architectural contrast with adjacent
hyperplastic tissue. In many instances, a clear-cut distinction
between nodular and diffuse hyperplastic areas is difficult or
impossible to make. Nodules appear to be enriched in oxyphil and
transitional oxyphil cells [73].
The tumor-like formations within an initially pure hyperplastic
tissue have long been thought to indicate some type of autono-
mous growth, corresponding probably to the so-called "tertiary
hyperparathyroidism." The control of PTH release by calcium is
abnormal in parathyroid cells obtained from such formations [74].
Vitamin D receptor expression is markedly decreased or even
entirely absent in nodule-forming areas [11]. Using in-situ hybrid-
ization and immunohistochemistry methods, we recently found
de-novo expression of transforming growth factor-a (TGF-a)
mRNA and protein in the parathyroid tissue of 15 hemodialysis
patients with severe secondary hyperparathyroidism in contrast to
no TGF-a expression in 5 normal parathyroid glands [751. We also
observed a marked expression of epidermal growth factor recep-
tor (EGF-R). Our finding suggests that, because TGF-a is known
to bind to EGF-R, increased interaction between this growth-
stimulating factor and its receptor promotes proliferation of
parathyroid cells, perhaps by an autocrine mechanism.
Polyclonal versus monoclonal growth. In a recent study [76], we
examined the clonality of parathyroid glands surgically removed
from dialysis patients who had severe hyperparathyroidism refrac-
tory to medical treatment. We used X-chromosome inactivation
analysis with the M27 (DXS255) DNA polymorphism; clonality
can be assessed from the proportion of female tumor cells in
which a particular X-chromosome is inactivated. Knowledge of
the genes involved in clonal transformation is not required to use
this technique. This method has previously been successfully
employed to demonstrate the monoclonal character of primary
parathyroid adenomas [77]. In the present study, we found a
prevalence of monoclonal neoplasms in 7 of the 11 female
hemodialysis patients studied (64%), and in 12 of 19 glands able
to be studied (63%). No correlation existed, however, between the
presence of macroscopically or microscopically evident nodules
and the clonal character of resected parathyroid tissue; several
glands with a diffuse hyperplastic appearance also were unequiv-
ocally monoclonal in the absence of detectable nodular forma-
tions. In the absence of available light microscopic criteria that
could allow us to distinguish diffuse hyperplasia from benign
neoplasia, we assumed that monoclonal uremic parathyroid
glands, which exhibited a pure hyperplastic appearance and no
visible nodules, corresponded to end-stage "nodular" transforma-
tion.
The fate of parathyroid gland fragments left in place after
parathyroidectomy or autografted into the forearm of uremic
patients could be linked to the presence or absence of monoclonal
neoplasms within that tissue. In our experience, the recurrence of
secondary hyperparathyroidism subsequent to the redevelopment
of parathyroid gland masses from tissue left in place after subtotal
parathyroidectomy was significantly greater in dialysis patients in
whom the removed parathyroid glands had a nodular appearance
than in those with diffuse hyperplasia alone [71]. As to parathyroid
autotranspiantation, autografted fragments isolated from diffuse
hyperplastic tissue are rarely responsible for recurrent hyper-
parathyroidism, in contrast to fragments isolated from nodular
parathyroid structures [78]. However, as I just pointed out, the
macroscopic or microscopic appearance of hyperplastic glands is
not as reliable in this respect as previously thought. In the past,
controversy surrounded the potential malignancy of such frag-
ments [79, 80]. We have never observed true malignancies, that is
metastatic cancer, originating from such tissue [801. The resolu-
tion of this debate probably lies in the nature of the autografted
tissue; in case monoclonal tissue is transplanted, benign, but not
malignant, neoplastic growth will occur. The finding, or absence of
finding, in rapidly growing parathyroid autografts of a deletion of
the recently described RB gene, characteristic of parathyroid
carcinoma, should allow us to resolve this issue definitively [811.
Figure 2 illustrates our current view of how parathyroid tissue in
chronically uremic patients progresses from polyclonal hyperplas-
tic towards monoclonal rieoplastic growth. Monoclonality implies
that somatic mutation of a gene or genes controlling cell prolif-
eration occurred in a single cell, conferring a selective growth
advantage upon it and its progeny. Our observation suggests that
monoclonal growth is not an exceptional event in parathyroid
hyperplasia secondary to long-standing chronic renal failure. In
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Fig. 2. Pathogenesis of secondaiy and "tertialy" hyperparathyroidism in chronic renal failure. Diffuse parathyroid hyperplasia progresses to hyperplasia
with nodular formations containing monoclonally growing cells, and eventually to diffuse invasion of the entire gland by monoclonal parathyroid cells.
fact, it appears to occur rather commonly, similarly to what has
been observed in familial multiple endocrine neoplasia type-i
(MEN-i), with parathyroid tumors exhibiting clonal DNA losses
in the putative MEN-i gene region [82, 83].
The factors involved in the emergence of monoclonal neo-
plasms within diffuse hyperplastic endocrine tissue have not yet
been elucidated. The impaired capacity of uremic patients to
repair DNA [84, 851 might play a role. Specific activation of
tumor-enhancing genes or deletion of tumor-suppressor genes are
good candidates. Examples from related pathologies include a
rearrangement or an overexpression of the PRAD1 oncogene in
association with benign parathyroid adenoma [86], an inactivation
of the RB tumor-suppressor gene as a key factor in the patho-
genesis of parathyroid carcinoma [81], and somatic loss of the
normal allele of the not-yet-isolated MEN-i gene in the 1 1q13
region of chromosome 11 [82, 83]. An allelic loss of this presumed
tumor-suppressor gene on 11q13 also was recently described in 2
of 12 parathyroid glands of dialysis patients [87]. However, we
failed to identify allelic DNA loss on ilql3 in any of the
parathyroid glands in the dialysis patients in our recent study [76].
It is also conceivable that somatic mutations of genes playing a
role in the regulation of PTH synthesis or secretion are involved,
including the vitamin-D receptor gene [88] and the recently
discovered calcium-sensing receptor genes [23, 24]. Mutations of
the former lead to tissue resistance to calcitriol, and are clinically
expressed as vitamin D-resistant rickets and secondary hyperpara-
thyroidism [89]. Mutations of the latter are responsible for the
familial hypocalciuric hypercalcemia syndrome with uncontrolled
PTH secretion [90].
Regression of parathyroid hyperplasia. Reversal of parathyroid
tissue hyperplasia in patients with chronic renal failure theoreti-
cally can be seen either with appropriate medical treatment or
after successful renal transplantation.
Regression probably is a slow process; it appears to proceed
mainly via apoptosis, not via cell necrosis [61]. On the other hand,
degenerative and necrotic changes do occur in a number of
parathyroid glands removed from dialysis patients with extensive
parathyroid hyperplasia ("tertiary hyperparathyroidism"), includ-
ing amyloid deposits, interstitial and intracystic hemorrhage, mild
to dense fibrosis, cholesterol granuloma, infarction of nodular
structures, and calcification [60]. However, such degenerative
alterations could reflect local response features to disordered
growth rather than a process of regulated involution. Even though
Fukagawa et al claimed, based on repeat neck ultrasound exam-
inations, that they have observed a rapid regression of parathyroid
gland size in hemodialysis patients after intravenous calcitriol
therapy [91], others have been unable to confirm this observation
[69, 92]. The latter results agree with experimental findings in
chronically uremic rats [61].
According to Parfitt, the markedly enlarged parathyroid gland
mass regresses very slowly after renal transplantation in patients
with hypercalcemic hyperparathyroidism [93]. The involution
often requires years despite the normalization of plasma calcium
and calcitriol levels. Even 10 years after transplantation, the
weight of the parathyroids has remained elevated in some patients
[93]. In another, more recent study, abnormal parathyroid func-
tion persisted for more than 6 months after kidney grafting in 8 of
ii normocalcemic patients [94]. Persistent hyperparathyroidism
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was apparent from baseline measurements in only 2 patients. In
the remaining 6 subjects, hyperparathyroidism could be diagnosed
only when the abnormal relation between circulating intact PTH
and ionized Ca2 levels was taken into account. The variability of
regression of parathyroid gland hyperplasia after successful renal
transplantation from one patient to the other probably is due to
several mechanisms, including persistence of some degree of renal
failure and possibly a stimulating effect of glucocorticoid treat-
ment on PTH secretion [951. Regression can even vary from one
gland to the other in a given patient, and adenoma-like lesions are
frequently observed when such patients undergo parathyroidec-
tomy [95]. It is possible that the major difference between
parathyroid glands that are amenable to involution and those that
are not lies in the type of growth, namely, monoclonal or
polyclonal, during the uremic state. The correction of renal failure
by a functioning renal graft could allow polyclonal hyperplasia to
regress, whereas monoclonal neoplasms would continue growing.
Our knowledge is sparse not only with respect to the velocity of
growth of parathyroid tissue in chronic renal failure, but also with
respect to possible mechanisms that allow parathyroid cells to
slow down or even stop growth. Calcitriol treatment might halt
parathyroid growth, but it probably cannot achieve regression
[611. It would be interesting to know whether hypercalcemia also
might downregulate increased growth in uremia, in particular, in
the case of clonal benign neoplasms. Using recent findings in
radiation-associated hyperparathyroidism, Parfitt and colleagues
hypothesized that the slowing of parathyroid tumor growth prob-
ably results from decreased cell birth, rather than from increased
cell death, be it by a process involving apoptosis or necrosis [621.
A similar mechanism might play a part in the growth of clonal
parathyroid neoplasms. Nodular growth cannot be an entirely
autonomous, deregulated process. If it were due to a mutation in
the set point of the parathyroid cell for presumed growth-
regulating factors such as calcium or calcitriol, an appropriate
change in the systemic or local concentration of such factor(s)
(favoring inhibition of growth) eventually could slow parathyroid
cell proliferation and maybe even monoclonal growth.
Future directions
Since the introduction of radioimmunologic assays that allow
measurement of plasma intact PTH, with its good correspondence
to bone histology findings, monitoring of parathyroid function in
uremic patients has been greatly improved. However, even though
the relation between circulating intact PTH levels and the secre-
tory function of the parathyroid glands appears to be excellent, a
similar correlation does not exist between plasma intact PTH and
total parathyroid cell mass. New ways must be found—using
quantitatively more precise methods than the currently available
ultrasound, magnetic resonance imaging, and scintigraphic tech-
niques—to directly assess parathyroid gland growth in uremic
patients with secondary hyperparathyroidism. We then would
have the ability to determine whether regression of hyperplasia
Occurs.
Moreover, it would be extremely helpful for us to know for each
parathyroid gland whether its cells are growing in a polyclonal or
monoclonal, tumor-like mode. This goal could be achieved by
performing an ultrasound-guided, fine-needle aspiration of en-
larged parathyroid glands. The cells harvested by this procedure
could be examined using clonal analysis by means of the poly-
merase chain reaction, as recently described for primary parathy-
roid adenomas [96]. An alternative solution would be to identify a
specific deletion or overexpression of growth-inducing or -repress-
ing genes that have still to be identified.
Questions and answers
DR. KARL M. KOCH (Professor of Medicine, Medizinische Hoch-
schule, Hannover, Germany): My question concerns the regression
of secondary hyperparathyroidism after successful renal trans-
plantation. In some patients hyperparathyroidism does not re-
gress, and these individuals have to undergo parathyroidectomy.
Does a specific parathyroid histology underlie this resistant,
secondary hyperparathyroidism after successful transplantation?
DR. DRUEKE: At the time of renal transplantation, a uremic
patient with secondary hyperparathyroidism may either have
diffuse parathyroid gland hyperplasia of polyclonal type growth, or
may have one or more monoclonally growing parathyroid glands.
In the first case, one would expect an involution of all hyperplastic
parathyroid glands to occur after successful transplantation. The
regression can take much time, given that it will take place mainly
through apoptosis of individual parathyroid cells, which is a very
slow process [62]. In the second case, a monoclonally growing
parathyroid gland mass would not regress, whereas in the same
patient, concomitantly existing polyclonal glands would undergo
involution. This could eventually lead to the discovery of single or
twin parathyroid adenomas when neck exploration is done several
years after transplantation. Such an evolution, differing according
to the predominant mode of tissue growth, would be compatible
with the observation made by the nephrology group from the
Hôpital Tenon in Paris, which reported that of 14 renal transplant
patients who underwent parathyroidectomy, 10 had parathyroid
hyperplasia, whereas 4 had parathyroid adenomas [95].
DR. F. PAOLO SCHENA (Chairman of Nephrology, University of
Ban, Ban, Italy): You showed an increased expression of growth
factors in hyperplastic parathyroid glands. Do you believe that this
increased expression is due to binding of PTH with its receptor on
the surface of parathyroid cells or to binding of calcium to its own
receptor?
DR. DRUEKE: The first part of your question addresses the issue
of whether PTH itself can regulate parathyroid cell growth. There
is no evidence for a direct PTH effect on the parathyroid cell.
There is also no evidence, to the best of my knowledge, for the
presence of PTH receptors in parathyroid tissue.
The second part of your question is related to the potential role
of Ca2 tsensing receptor in the increased expression of growth
factors. This is indeed an important question. Is the decrease in
extracellular calcium acting only through the stimulation of
parathyroid hormone synthesis and secretion, or is it also linked
independently to the local expression of growth factors, as for
instance TGF-alpha, acidic fibroblast growth factor, or others?
We have no answer for this question at present. Obviously we
need an in-vitro model of human parathyroid cells in culture,
where cells can be maintained in a viable state for several passages
and remain able to modulate parathyroid hormone synthesis and
secretion in response to exogenous stimuli, and as low external
Ca2 concentration, in contrast to currently available systems
[97]. Such a model would allow us to address this issue specifically.
My collaborator Jean Gogusev has recently succeeded in estab-
lishing viable human parathyroid cells in long-term culture.
Therefore, we should be able to study parathyroid cell growth
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independently from PTH synthesis and secretion in the near
future.
DR. DANIEL CORDONNIER (Professor, Centre Hospitalier Univer-
sitaire, Grenoble, France): You mentioned severe aluminum intox-
ication in your patient's dialysis course. Its treatment was followed
by a recurrence of hyperparathyroidism. By contrast to the first
episode of hyperparathyroidism, the second one was secondary.
Could you comment on the role of aluminum as a factor promot-
ing or facilitating secondary hyperparathyroidism?
DR. DRUEKE: I am not sure that the first episode was primary
hyperparathyroidism. This patient had long-standing chronic re-
nal failure. It could well be that because of the prolonged uremic
state, she developed a clonal cell line within one of her four glands
that was then growing more rapidly than the three other glands.
Such clonal cell growth eventually led to an adenoma, which in
addition repressed the development of the other glands. So even
the first episode might have been secondary hyperparathyroidism,
but of the benign monoclonal type growth.
At present, it is impossible to make a specific diagnosis in vivo.
Even tissue sampling would not allow us to distinguish primary
from secondary benign neoplasia. This issue may be solved by
identifying the mutation(s) that could be involved in the particular
evolution from polyclonal towards monoclonal growth.
It has long been known that aluminum intoxication interferes
directly with PTH secretion. Several in-vitro studies using acutely
surviving parathyroid cells have shown that when the aluminum
concentration is increased in the incubation medium, PTH secre-
tion decreases [43, 44]. In terms of aluminum and parathyroid cell
growth in vitro, nothing is known because no good model has been
available for such studies. Agnes Bourdeau and colleagues at the
Hôpital Necker have provided evidence of several histologic and
ultrastructural changes of parathyroid cells induced by aluminum
in vitro [44]. Aluminum also can be deposited in the mitochondria
in vivo and thereby could directly interfere with the respiratory
machinery of the parathyroid cell and eventually lead to cell
necrosis in case the intoxication is severe [98].
DR. YVES PIRs0N (Associate Professor, University of Louvain
Medical School, Brussels, Belgium): The sequence of events you
have described, from hyperplasia to nodule formation and ade-
noma, has an important clinical counterpart. We treat the sec-
ondary hyperparathyroidism of our patients who have chronic
renal failure with calcitriol. This treatment is not without danger,
however. It is expected that only patients at the precise stage of
hyperplasia will respond to calcitriol. My question is: can we
clinically identify the precise stage of hyperparathyroidism in our
patients before embarking on calcitriol treatment?
DR. DRUEKE: At present, we have no means of identifying
patients who have monoclonal type growth or polyclonal type
growth except when the patients undergo surgery and we can
analyze the glands after they have been removed. Obviously our
goal is to identify such different types of growth long before
parathyroidectomy. It is already possible to perform ultrasound-
guided puncture of parathyroid tissue, at least in ultrasound-
identifiable hyperplastic glands of such patients. That is, we can
direct a fine needle into the parathyroid tissue, aspirate cells, and
make cytologic and biochemical analyses (PTH). It may become
feasible to examine the type of growth by X-inactivation analysis
or by identifying gene mutations using PCR technique in case they
are shown to be involved in a major way in monoclonal type
growth.
DR. PJRSON: Still, is it wise to give calcitriol at the stage of
nodular hyperplasia?
DR. DROEKE: There is no answer to this question at present.
Edward M. Brown, when doing in-vitro studies on parathyroid
glands from uremic patients more than 10 years ago, found that
some of them were more inhibitable than others [99]. He thought
that there were different types of growth or different sensitivities
to extracellular calcium. The sigmoidal calcium-PTH relation that
was studied in vitro indicated that PTH release from some glands
of some patients was better inhibited or stimulated than from
others. Therefore, some glands from uremic patients with severe
secondary hyperparathyroidism could be less responsive than
others; parathyroid gland nodules that have decreased calcitriol
receptor numbers could respond to a high calcitriol treatment less
well or even not at all, Ideally, one could imagine that we could
predict the response to calcitriol in vitro, using parathyroid tissue
sampled by fine-needle aspiration, after having identified the type
of growth.
DR. DONTSCHO KERJASCHKI (Professor of Pathology, University of
Vienna, Vienna, Austria): Parathyroid epithelial cells are endowed
with huge amounts of gp330, a Ca2 binding protein that is also
the nephritogenic antigen of Heymann nephritis. Recent work
from a Swedish group indicated that gp330 also could serve as a
Ca2 sensor [100]. Do you have any comments?
DR. DRUEKE: I have not yet seen this recent work, so I am afraid
I cannot comment on this interesting possibility.
DR. FERNANDO VALDERRABANO (Professor of Medicine, and
Chairman, Department of Nephrology, Hospital General Universita-
rio Gregorio Marañon, Madrid, Spain): My question is about the
role of metabolic acidosis. Several studies have shown that
metabolic acidosis induces a net calcium efflux from bone in vitro,
although this effect is not seen in respiratory acidosis [101, 102].
There also is some in-vivo evidence for a possible role of
metabolic acidosis in the development of parathyroid hyperplasia.
Lefebvre et a! showed progression of secondary hyperparathyroid-
ism in acidemic hemodialysis patients [45]. This effect was not
seen in patients whose acidosis was corrected.
DR. DRUEKE: The effect of acidosis on bone is the result of a
complex interaction of various factors. As you correctly point out,
metabolic acidosis appears to cause direct effects on bone, de-
creasing not only bone formation but also increasing bone resorp-
tion. This issue has been addressed in a number of elegant studies
by Bushinsky and colleagues [102]. In addition to its direct effects
on the skeleton, metabolic acidosis also exerts indirect effects via
its influence on PTH secretion and vitamin D metabolism.
Lowering the pH of the incubation medium of isolated parathy-
roid cells led to a decrease in PTH release after a previous
maximal stimulation by low-calcium medium, but a possible pH
effect on basal PTFI secretion was not studied [103]. However,
in-vivo evidence from Paillard's group in Paris suggests a stimu-
latory effect of acute metabolic acidosis on PTH secretion in rats
[104]. The work by Lefebvre and colleagues in Paris points in the
same direction; they showed in chronic hemodialysis patients that
an optimal long-term correction of metabolic acidosis was asso-
ciated with a decrease in the progression of hyperparathyroid
bone disease [45]. Metabolic acidosis also decreases calcitriol
production [105, 106], probably by increasing ionized calcium in
proximal tubule mitochondria [1071, and could thereby influence
bone turnover. However, the issue of a potential modification of
vitamin D metabolism by acidosis remains controversial [108].
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DR. VALDERRABANO: In our experience, nodular hyperplasia is
much more frequent than is diffuse hyperplasia in parathyroid
glands surgically removed from dialysis patients. This fact could
explain the high frequency of recurrence of hyperparathyroidism
that we see.
DR. DRUEKE: We found in a study that we did at the Hôpital
Necker 11 years ago that nodule formation in parathyroid glands
increased with time on hemodialysis [63]. In our more recent
study on the fate of parathyroid function in hemodialysis patients
after subtotal versus total parathyroidectomy followed by imme-
diate autotransplantation, we found a higher number of patients
with purely hyperplastic glands than with nodular glands: 26
versus 18 patients [71]. Maybe you operate on your patients later
than we do. It is possible you are better doctors than we are and
you are more successful than we are in keeping the patients in
acceptable osteoarticular conditions for longer time periods. It is
clear that patients who have been on dialysis for more than 10
years have a higher nodule prevalence than do patients who have
been on dialysis for less than 10 years.
DR. MICHEL OLMER (Professor of Nephrology, and Chief Neph-
rology-Dialysis Unit, Hôpital de Ia Conception, Marseille, France):
Secondary hyperparathyroidism can progress to adenoma. Is
hyperplasia of parathyroid cells the first obligatory step in such
instances? Are there some specific factors that can influence or
predict the likelihood of this progression?
DR. DRUEKE: It is highly probable that in most instances, diffuse
parathyroid hyperplasia is the first event in all patients who
develop hyperparathyroidism in the setting of chronic renal
failure. There may, however, be a primary adenoma in the
exceptional case. No definite answer can be given at present to the
question of how to distinguish a primary adenoma from a
secondary nodular growth. In dialysis patients, in case you have
four glands which, for instance, weigh 2000 mg, 1000 mg, 200 mg,
and 50 mg, respectively, this constellation is suggestive of second-
ary hyperplasia as the first event. In case of a primary adenoma in
one gland, the other three glands should be hypotrophic. There is
no reason to believe that three primary adenomas develop at the
same time.
DR. Kocu: The concept of a change in the calcium set-point of
parathyroid cells originates from the clinical observation of hy-
percalcemia due to to severe, secondary hyperparathyroidism. As
an alternative explanation, it was postulated that "tertiary hyper-
parathyroidism" could be caused by excessive glandular mass,
since with a very large increase of parathyroid cells—even at basal
hormone secretion of these cells—one would see increased PTH
levels even in the presence of hypercalcemia. Could you please
comment?
DR. DRIJEKE: It is true that an excessive increase in parathyroid
tissue mass per se should lead to hypercalcemia. This has been
experimentally demonstrated in rats that have received a great
number of parathyroid glands transplanted from isogeneic ani-
mals. However, if the excessive parathyroid mass were solely due
to calcium deficiency, it would not seem reasonable to expect the
development of hypercalcemia. Therefore other factors must be
involved. An alteration in the sensitivity of the parathyroid gland
to calcium has been found by some, but not by others, probably
because of marked methodologic differences between studies [151.
The recent, carefully done study by Salusky's group in Los
Angeles, California, concludes that the set point and the slope of
the sigmoidal calcium/PTH curve are no different in adolescent
uremic patients on continous ambulatory peritoneal dialysis and
healthy control subjects [30]. Whether their conclusion also holds
for adult hemodialysis patients remains to be seen. The sensitivity
of the recently cloned calcium-sensing receptor [23] might well be
altered, at least in a subset of uremic patients. For instance, the
sensitivity of the receptor could be different in the case of nodular
transformation of parathyroid tissue, similar to the reported
decrease in the number of calcitriol receptors [11]. On the one
hand, a recent preliminary study in uremic rats failed to detect a
change in the mRNA expression of the parathyroid calcium-
sensing receptor [109]. On the other hand, histochemistry studies
done by the Swedish group of Akerström and colleagues revealed
reduced and heterogeneous staining on parathyroid tissue of
uremic patients, with antibodies directed against a calcium sensor
on the cell surface, compared with normal parathyroid tissue [73,
110]. The high-molecular-weight calcium sensor recognized by
these antibodies was recently cloned by this group [100]. This
cDNA encodes a 500 kDa protein that belongs to the LDL-
receptor superfamily and therefore is different from the one
cloned by Brown and colleagues [11].
I am confident that in the near future we will know much more
about calcium-sensing receptors in the parathyroid tissue and
elsewhere, and about the possible implications of the parathyroid
cell calcium-sensing mechanism in the pathogenesis of secondary
hyperparathyroidism.
DR. PHILIPPE JAEGER (Professor of Medicine, and Director,
Policlinic of Medicine, University Hospital, Berne, Switzerland):
What is the role of the calcium channel in secondary hyperpara-
thyroidism, in view of the fact that calcium-channel blockers
influence PTH secretion? Is it possible that, for whatever reason,
maybe genetic, this channel could be abnormally conformed in
patients with uremia?
DR. DRUEKE: To the best of my knowledge, no calcium channel
has thus far been formally characterized in the parathyroid cell.
However, I fully agree with you that the experiments with
calcium-channel-blocking agents in parathyroid tissue in vitro are
highly suggestive of the existence of a receptor-gated calcium
channel.
DR. PIERRE COCFIAT (Pediatric Renal Unit, Edouard Herriot
Hospital Lyon, France): Do you have information on the distri-
bution of growth factors, that is, TGF or EGF, in the parathyroid
glands of patients with primary hyperparathyroidism?
DR. DRUEKE: Yes, in a parallel study that we did in the
laboratory but which I didn't have time to discuss today, we also
examined the expression of TGFc, EGF, and EGF receptor in
patients with primary adenoma. There also was an overexpression
of TGFa mRNA and protein, compared with normal parathyroid
tissue (Gogusev et al, unpublished results).
DR. COCHAT: Does the same distribution exist in secondary
hyperparathyroidism?
DR. DRUEKE: It is premature to give definite conclusions on
distribution at present. We observed a focal type of distribution of
the TGFc message and protein in the glands of some patients
discussed earlier for TGFn mRNA. In others, there was diffuse
overexpression, whereas in the control tissue of normal glands,
there was no expression at all. It might be that only in a gland with
both nodule formation and hyperplasia could overexpression
become visible, but we need more experience. In the 15 patients
with severe secondary hyperparathyroidism studied by us, we have
observed many different distribution patterns. It is difficult for me
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at present to make any definite statements in this area. We hope
to reach a better understanding by looking at subgroups of
patients and subtypes of histology.
DR. GREGORY U. VOSNIDES (Chief Division of Nephrology,
Laiko General Hospital, Athens, Greece): It has been suggested
that calcitriol administration reduces parathyroid hyperplasia,
although this hypothesis has not been confirmed. Would you say
that calcitriol should be tried in everyday practice and if no
reduction in size is observed, then other treatments, for example,
parathyroidectomy, should be carried out?
DR. DRUEKE: The possibility of a reduction of hyperplastic
parathyroid glands in uremic patients subsequent to medical
treatment remains a controversial issue. Therefore, the absence of
visible regression by ultrasound examination is by no means
sufficient to abandon medical therapy, such as calcitriol and/or
oral calcium, in favor of surgical parathyroidectomy.
DR. VOsNIDEs: What is the impact of very early calcitriol
administration on the natural history of parathyroid hyperplasia
of chronic renal failure? How do you recognize the problem, and
what do you do practically, in patients who respond or don't
respond to calcitriol?
DR. DRUEKE: Prevention or treatment of secondary hyperpara-
thyroidism is much easier to achieve in the early stages of chronic
renal failure than at later stages. There are two schools of thought
as to the best initial therapy. The first advises us to commence
with oral calcium supplements and to refrain from prescribing
active vitamin D derivatives. The other school of thought advises
us to administer calcitriol or 1 -alpha-OH-cholecalciferol. Dog-
matic viewpoints may be deleterious to the patient. In fact,
treatment should be adapted to each patient's individual condi-
tion. Thus, in the patient who has no increase in serum calcium or
phosphorus, as is generally the case in early renal failure, small
daily doses of calcitriol or 1-alpha-OH-cholecalciferol, together
with small amounts of oral calcium, may be the preferred therapy.
In patients with uncontrolled hyperphosphatemia and/or soft
tissue calcifications, that is, generally during more advanced stages
of renal failure, the administration of vitamin D derivatives is
contraindicated. In case of hypercalcemia and/or soft tissue
calcifications, the administration of large amounts of oral calcium
also is contraindicated. Note that treatment with both excessive
vitamin D and excessive oral calcium can lead to adynamic bone
disease.
DR. LORETO GESUALDO (Institute of Nephrology, University of
Bari Bari Italy): I found your hypothesis on monoclonal and
polyclonal growth fascinating. Could you please speculate on the
factors that can induce somatic mutation leading to monoclonal
growth of parathyroid tissue?
DR. DRUEKE: This issue is the subject of intensive work in my
laboratory. At present, we are left with speculations. There could
be a tumor-suppressor gene, the expression of which is decreased,
or a tumor-enhancer gene, the expression of which is increased.
There are several candidate oncogenes involved in tumor growth,
but thus far we have no special candidate. Another possibility is
that one of the receptor proteins implicated in the response of the
parathyroid cell to calcium or calcitriol could be changed in
qualitative or quantitative terms, for instance, a change in the
affinity or number of the calcium receptors. This change could
stimulate PTH secretion and growth. On the other hand, a
decrease in VDR number has been documented, at least in
discrete areas of the hyperplastic parathyroid gland [11]; this
decrease could contribute to a diminished transmission of the
VDR-hormone complex to the promoter of the PTH gene. If
there were a change, such as a mutation of the VDR gene, in one
cell at some time, this could lead to the selection of a parathyroid
clone that could overgrow the other cells.
DR. NIcoLAos E. MADIAS (Chief Division of Nephrology, New
England Medical Center, Boston, Massachusetts): Could you please
give us some information on the structure, function, and possible
interrelationship between the Ca2-responsive and the vitamin
D-responsive elements of the PTH promoter?
DR. DRUEKE: I'm not a molecular biologist. I cannot give you a
specific answer to that question.
DR. MADIAs: You mentioned that the threshold of PTH secre-
tion in response to lowering Ca2 level differs among PTH cells.
Is this threshold stable in a given cell, and does it relate to its
complement of vitamin D receptors?
DR. DRUEKE: As far as I recall, the Mayo Clinic group correctly
found that with time and decreasing calcium concentration, more
and more parathyroid cells are recruited to secrete PTH, but only
up to 75%. It is imaginable that if the experiment were extended
to 48 hours or more of low-calcium stimulation, maybe all the cells
would have been recruited to secrete PTH, but technically the
in-vitro model would not allow study over such prolonged time
periods. It is probably not known whether this threshold, or the
degree of relative resistance to low external calcium, is stable in a
given cell, and whether it depends on each cell's status in terms of
vitamin D-or calcium-sensing receptor.
DR. LAJ'4DIN0 ALLEGRI (Institute of Medicine and Nephrology,
University of Parma, Parma, Italy): The occasional finding of
autoantibodies against parathyroid hormone in uremic patients
has raised the question whether autoimmune mechanisms could
have some role in the genesis of secondary hyperparathyroidism.
Can you comment on this subject?
DR. DRUEKE: I believe that autoantibodies against PTH only
have been reported in hypoparathyroid patients, but not in
hyperparathyroid patients. In contrast, the occurrence of autoan-
tibodies against the PTH receptor in uremic patients was de-
scribed many years ago by the group of Dr. Hesch in Hannover,
Germany [111]. A potential interference of these circulating
immunoglobulins with PTH binding to its receptor was discussed
but remained uncertain.
DR. JORDAN J. COHEN (President, Association of American
Medical Colleges, Washington, D.C.): Do we know what precise
component of uremic serum is responsible for interfering with the
calcitriol-VDR complex's action within the nucleus of the para-
thyroid cell?
DR. DRUEKE: Chen H. Hsu's group in Ann Arbor, Michigan,
has been working recently with R. Vanholder from Belgium to
identify the uremia-related factor(s) that could be involved in the
modified metabolism of 25-OH-vitamin D to 1,25-diOH-vitamin
D in renal failure [1081. They found that purine compounds such
as uric acid, xanthine, and guanidinosuccinic acid decreased
calcitriol production rate. They published a study very recently on
diminished transfer of the VDR complex into the nucleus in vitro
in the presence of uremic ultrafiltrates [112]. No specific inhibi-
tory substance was identified for nuclear uptake interference,
however.
DR. JOHN T. HARRINGTON (Dean for Academic Affairs, Tufts
University School of Medicine, Boston, Massachusetts): Could you
speculate on the factors involved in the focal expression of TGFa
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within solely hyperplastic glands, that is, the glands without
nodular transformation?
DR. DRUEKE: I am not sure that the overexpression of TGFa
was only focal, even though it might have been more marked in
focal areas. A focal overexpression of TGFa messenger RNA and
protein would theoretically go along with a focal activation of
parathyroid cells. We've known for a long time from examining
PTH expression in the parathyroid tissue that differences exist
from cell to cell and also from area to area. Such studies have
been done before the knowledge of monoclonal type growth,
suggesting functionally active and inactive areas within the para-
thyroid gland. At present, we have to reconsider the meaning of
such focal differences in terms of monoclonally versus polyclonally
growing cells.
DR. CHRISTOPHER G. WINEARLS (Consultant Nephrologist, Renal
Unit, The Churchill Oxford Radcliffe Hospital, Oxford, UK): What
are the implications of the finding of monoclonality in parathyroid
glands in the practice of autografting this tissue after parathyroid-
ectomy?
DR. DROEKE: Theoretically, one should not autotransplant
nodular-type hyperplastic tissue. If you transplant primary ade-
noma cells into the forearm, they regrow in a rapid, autonomous
manner. In case of secondary hyperplasia with massive nodular
formation, the surgeon should stay away from this nodular tissue
and choose tissue from other glands with pure hyperplasia.
However, you may have a gland with a diffusely hyperplastic
appearance and yet this still might be a monoclonal neoplasm. In
the future, it may become possible to make the diagnosis of
polyclonal versus monoclonal growth on the basis of a parathyroid
gland biopsy, as recently described for primary parathyroid ade-
noma [961.
DR. KOSTAS C. SIAMOPOULOS (Associate Professor of Medicine!
Nephrology, University Hospital of loannina, Joannina, Greece):
Apart from the growth factors you mentioned, did you look for
others, that is, angiotensin II, a potent growth factor that could be
modulated by drugs?
DR. DRUEKE: We didn't look at angiotensin II because there is
no clinical or experimental evidence that angiotensin II has a
direct effect on parathyroid gland tissue. I am not aware of
anybody having examined this question. We have preliminary
evidence that the p53 protein and the retinoblastoma gene are not
deleted in hyperplastic parathyroid glands from uremic patients.
We also have started examining calcium-sensing receptor expres-
sion in those glands, and I hope we will have information in the
near future.
DR. PIERRE RoNco (Professor of Nephrology, Hôpital Tenon,
Paris, France): Mitogenesis and hyperplasia are often, if not
always, associated with stimulation of the mitogen-activated pro-
tein kinase cascade leading to activation of NFKB and AP-1
transcription factors. This cascade is activated by occupancy of
receptors coupled to tyrosine kinase, including EGF receptors.
Are you aware of any study that has looked at this important
mitosis pathway at the various steps that you described from
hyperplasia to monoclonal proliferation?
DR. DROEKE: I am not aware of any such studies. There are in
fact only few studies on parathyroid cell growth. We will have to
work hard to analyze more appropriately all the factors potentially
involved in increased mitogenesis.
DR. ARTURO BORSATII (Professor of Nephrology, University of
Padova, Padova, Italy): What controls calcitriol receptor synthe-
sis? Is it only calcitriol? Do adenomatous cells respond to
calcitriol, in terms of calcitriol receptor synthesis, like normal
parathyroid cells?
DR. DRUEKE: In the regulation of the expression of calcitriol
receptor, calcitriol itself is clearly the most important factor
involved. I am not sure whether other factors are involved in the
regulation of the calcitriol receptor. An important recent finding
is the observation that retinoid X receptors, a newly discovered
class of nuclear receptors, form heterodimers with the VDR and
might be involved in the high-affinity binding of VDR to vitamin
D-responsive elements at the PTH gene level [113]. As to the
response of adenomatous cells to calcitriol, compared with normal
parathyroid cells, this issue has not yet been addressed.
DR. GIUSEPPE REMUZZI (Director, Mario Negri Institute, Ber-
gamo, Italy): In search of uremic toxins, possibly implicated in
vitamin D metabolism, you mentioned guanidinosuccinic acid.
This is a major substrate for nitric oxide generation, as is arginine.
As a consequence, nitric oxide is formed in excess amounts in
uremia and has been recently regarded as a novel "uremic toxin."
Given its multiple actions as intercellular messenger, it would be
nice to investigate whether nitric oxide inhibitors influence vita-
min D metabolism and PTH synthesis.
Du. DRUEKE: I thank you for this interesting suggestion.
DR. JOHN DONOHOE (Consultant Nephrologist, Beaumont Hos-
pita4 Dublin, Ireland): What is the best method for localizing
ectopic hyperparathyroid glands that have already eluded one, or
two, surgical neck explorations? Could monoclonal antibodies be
injected systemically to find these elusive glands?
DR. DRUEKE: Optimal localization methods in identifying ec-
toptic parathyroid glands of uremic patients that have not been
located by the surgeon during the first or second neck exploration
include, in my experience, ultrasonography by an experienced
radiologist for remaining glands in the neck region, that is, located
above the manubrium sterni; CT scan and!or MRI for the
localization of retrosternal glands; and 99Tc sestamibi, a recently
developed radioisotope technique, for any localization. The latter
method, which already has had good success in the diagnosis of
primary hyperparathyroidism, still must be validated for second-
ary hyperparathyroidism. Finally, venous catheterization may be
indicated in exceptional cases, to obtain focal differences in
plasma PTH concentration.
DR. HARRINGTON: Can we eliminate hyperparathyroid glands
without surgery?
DR. DRUEKE: Have we any means of destroying polyclonal
hyperplastic glands or monoclonal benign neoplasms directly,
without surgery? The only way at hand is to inject small amounts
of absolute alcohol. Several reports have appeared recently
[114—118] after the initial Italian experience from Milan [119].
Alcohol injection into the gland might be helpful in the control of
secondary hyperparathyroidism. In our hands, alcohol injection
was not successful in 4 of 5 patients, but we probably injected too
much alcohol.
DR. ALLEGRI: Are the ultrastructural features of parathyroid
glands in uremic patients of clinical value in the cases of difficult
differential diagnosis among hyperplasia, adenoma, and perhaps
carcinoma?
DR. DRUEKE: I'm not sure at present that ultrastructural
examination will be of great help in differentiating monoclonal-
type from polyclonal-type parathyroid cell growth. This conclu-
sion was reached in a recent study, in which it proved impossible
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to distinguish nodular from diffuse hyperplastic parathyroid
growth by morphology alone [601. If we become able to identify
specific features of different growth rates using electron micros.
copy, this might be of great help.
DR. ALEX M. DAvIsON (Consultant Renal Physician, St. James's
University Hospital, Leeds, UK): May I make a case for alcohol
injection in the treatment of tertiary hyperparathyroidism? In the
hands of an experienced operator who is using the technique,
frequently the results obtained can be very good [119]. For a
number of elderly and frail patients, this percutaneous approach
is the treatment of choice because of their unsuitability for
surgery.
DR. DRUEKE: I fully agree.
Reprint requests to Dr. T DrOeke, Director, INSERM Unite 90, Hôpital
Necker, 161 Rue de Sèvres, 75743 Paris, Cedex 15, France
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